MINNEAPOLIS, March 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the fourth quarter and full year 2023 after the market closes on Wednesday, March 27, 2024. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call Information To p ...

MINNEAPOLIS, March 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the fourth quarter and full year 2023 after the market closes on Wednesday, March 27, 2024. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call Information To ...

MINNEAPOLIS, March 06, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Leerink Partners Global Biopharma Conference 2024 to be held in Miami on March 11-13, 2024. Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, is scheduled for a podium presentation at 8:40 a.m. ET on Wednesday, March 13, 2024. A live webcast of the event will be available using ...

MINNEAPOLIS, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in Cowen's 44th Annual Health Care Conference to be held in Boston on March 4-6, 2024. Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, is scheduled for a fireside chat at 2:10 p.m. ET on Wednesday, March 6, 2024. A live webcast of the event will be available using this weblink https:/ ...

This concludes today's teleconference. You may disconnect your lines at this time. Thank you for your participation. Celcuity Inc. (NASDAQ:CELC) Q3 2023 Earnings Conference Call November 13, 2023 8:00 AM ET Maria Yonkoski - Investor Relations, ICR Brian Sullivan - Chief Executive Officer and Co-Founder Vicky Hahne - Chief Financial Officer Conference Call Participants Boris Peaker - Cowen Alex Nowak - Craig-Hallum Operator Greetings, and welcome to the Celcuity Third Quarter 2023 Financial Results Conferenc ...

(Mark One) OR Commission File No. 001-38207 16305 36th Avenue North; Suite 100 Minneapolis, Minnesota 55446 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 CELCUITY INC. (Exact name of registrant as specified in its charter) (Address of principal executive offices, including zip code) Registrant's telephon ...

Company Participants Brian Sullivan – Chief Executive Officer and Co-Founder Conference Call Participants Boris Peaker – Cowen Good afternoon, ladies and gentlemen, and welcome to the Celcuity Second Quarter 2023 Earnings Conference Call. At this time, all lines are in a listen-only mode. Following the presentation, weÂ'll conduct a questionand-answer session. [Operator Instructions] This call is being recorded on Thursday August 10, 2023. Celcuity Inc. (NASDAQ:CELC) Q2 2023 Earnings Conference Call August ...

At June 30, 2023, the Company's authorized capital stock consisted of 65,000,000 shares of common stock, of which 22,081,893 shares were outstanding, and 2,500,000 shares of preferred stock, including 1,850,000 shares designated as Series A Preferred Stock, of which 1,085,873 shares were outstanding. As of June 30, 2023, no dividends have been declared on the Company's capital stock. All assumptions used to calculate the grant date fair value of non-employee options are generally consistent with the assumpt ...

Our non-GAAP adjusted net loss for the first quarter of 2023 was $10.2 million or $0.47 loss per share compared to non-GAAP adjusted net loss for the first quarter of 2022 of $7 million or $0.47 loss per share. General and administrative expenses were $1.3 million for the first quarter of 2023, compared to $0.8 million for the first quarter of 2022. The approximately $0.5 million increase was a result of non-cash, stock-based compensation and professional fees associated with being a public company. With th ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OR For the transition period from to Commission File No. 001-38207 Delaware No. 82-2863566 (State of incorporation) (IRS Employer Identification No.) 16305 36th Avenue North; Suite 100 Minneapolis, Minnesota 55446 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share CELC The Nasdaq Stock Market LLC Indicate by ...